Articles On Bioxyne (ASX:BXN)

Bioxyne (ASX: BXN) subsidiary Breathe Life Sciences UK has received approximately $1.7 million in funding from economic development agency South of Scotland Enterprise (SOSE) to establish its UK medicinal cannabis manufacturing and distribu...

Two dozen esteemed sector figures recently gathered over lunch to recount their career highs and lows One luminary recalls an uncomfortable close encounter with a drug cartel, while others overcame the impact of academic and corporate frau...

Poor Chinese relations, Covid, war and US tariffs prove too much for device maker Uscom The Mayne Health takeover deal isn’t over, but the prognosis is dire Bioxyne strikes medical cannabis vape import deal   Uscom bows out Uscom (ASX:UCM...

Pfizer has become the first Big Pharma company to sign a pricing deal with the Trump administration Bioxyne has the dope on likely US medical pot reforms Paradigm trial gets a knees-up with its first patient dosed The Trump administration...

• Several emerging life science plays are taking revenue to new heights – and some have even turned profitable • Little Green Pharma seeks to avoid a second pay ‘strike’ • Althea founder exits the building   It is a truth, universally ackn...

Cannabis suppliers are struggling to differentiate themselves in a commoditised market Regulators have lax telehealth prescribers in their sights Althea Group has sold its medical pot arm in favour of THC-infused beverages     Having spro...

Highlights Bioxyne outpaces sector peers with performance in cannabis and health products Paradigm Biopharmaceuticals secures convertible note funding for late-stage trial Recce Pharmaceuticals and Botanix turn to debt as eq...

Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector’s best EOFY performer has come from left field: the local and Europ...

Bioxyne (ASX: BXN) has received certificates of Good Manufacturing Practice (GMP) compliance under mutual recognition agreements with five countries. The company’s wholly owned subsidiary Breathe Life Sciences – a GMP-licensed manufacturer,...

Diversified health products company Bioxyne (ASX: BXN) has upgraded its full-year revenue guidance for financial year 2025 by $3 million to $28m. The upgrade follows reported revenue of $12.6m for the first six months of the year, which rep...

ASX jumps 0.52pc to hit new 50-day high Market broadly higher, with 9 of 11 sectors firmly in the green Gold Index surges 4.99pc, with ASX gold companies following suit   It was a day of strength for the ASX, rising 0.52% to hit a new 50-...

Highlights Energy and uranium stocks supported market strength amid global trade discussions ASX 200 rose alongside the ASX Small Ords and ASX 200 Resources indices Standout moves from TMX, MDR, ZIP, KLS and multiple uranium...

US Secretary of the Treasury Scott Bessent is expected to meet with senior Chinese officials on Thursday Oil price hike lifts Energy sector more than 2pc Healthcare weighs on market under tariff shadow, down more than 1pc   The ASX has bu...

Aroa says the real impact from the 10% US tariff imposed on New Zealand goods will be much less than that Quarter time scores show companies are kicking with the wind Dimerix shares enter trading halt ahead of licensing deal   Kiwi wounds...

Trump’s tariffs shake markets, billions wiped off ASX Gold shines as trade war fears spark safe haven rush China, EU prep retaliation as global recession fears rise   Trump’s tariffs have hit markets hard, wiping almost $30 billion off th...

Donald Trump exempts “pharmaceuticals” from his tariff blitz ASX device makers mull their US manufacturing plans as Ansell shares plunge Race and Imugene progress their early-stage oncology trials   Liberation Day has spared the pharmaceu...

Bioxyne receives firm commitments to raise $3 million via strongly supported placement Funds to support European expansion and establish medicinal cannabis manufacturing facilities in UK and Czechia Directors to participate in the amount o...

Recent study shows psilocybin can heal brain injuries, boost neural connections ASX-listed Tryptamine tackles binge eating with psilocybin trials Bioxyne pioneers psilocybin production in Australia   Psilocybin is the naturally occurring...

ASX slides again, seven losses in eight days Copper tariff talk spooks miners, Rio and BHP down Woolies, Platinum, and Flight Centre also take a hit   It was another rocky ride for local stocks today, with the ASX 200 benchmark down by 0....

The S&P/ASX 200 rose 5% in January to reach a new record high Utilities was the only sector to fall in January with financials the top performer AusQuest tops January winners up 388% with discovery of a large-scale Peruvian copper pros...

The S&P/ASX 200 fell 3% in December as Santa rally failed to eventuate yet again  Consumer staples led the S&P/ASX 200 sectors in December with tech leading overall in 2024 Niobium and rare earths explorer Aldoro Resources led the...

From artificial intelligence (A.I) to zygotes, the biotech sector this year delivered the A to Z of excitement, intrigue, occasional disappointment and downright disaster. His virtual stethoscope on hand, Dr Boreham was on duty to diagnose...

ASX loses momentum after near-record high Tech stocks lead, but CSL falls; retail sales rise 0.6% in October Northern Star to buy De Grey for $5 billion   The ASX has lost some of its early momentum today, pulling back from a record high...

ASX rises on rally across the board Israel and Hezbollah agree to 60-day ceasefire City Chic tumbles after downbeat update   The Aussie share market enjoyed a solid ride on Wednesday, driven by a broad rally as optimism from Wall Street’s...

Chinese shoppers have not lost their appetite for EZZ’s health and beauty products Ho-Ho-Ho (Chi Minh)! Viet deal is an early Xmas prez for Truscreen holders Patrys says it will focus on its Plan B drug candidate   China is a tough consum...

Robert F Kennedy Junior’s appointment as US health czar means an unpredictable time for ASX healthcare companies operating in the US The likely consequences are not all bad, with many stocks poised to benefit from tax cuts and a more effic...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

ASX200 hits record high driven by US Fed interest rate cut Mining stocks surge as iron ore prices rebound ALS shares drop 10pc, Monadelphous rises on new contracts   The ASX200 hit yet another record high today, boosted by the first inte...

ASX closes higher as CBA and Macquarie touch records Lotus Resources finds significant uranium; gold stocks await US CPI data UBS favours ASX banks over miners   The ASX bounced back by 0.4% on Tuesday after  yesterday’s slump, with the...

S&P/ASX 200 recovers from heavy volatility early in the month to finish up 0.47% in August S&P Dow Jones Indices said mid-caps led the gains putting them ahead of large and small caps YTD Larvotto Resources rose on the back of Chin...

The ASX lagged on Thursday after Nvidia’s disappointing Q3 guidance Mineral Resources fell 8pc off a major profit drop Qantas saw a 28pc drop in profit but saw modest share price gains   The ASX was sluggish on Thursday, down 0.33%, follo...

Stockhead’s Fraser Palamara sits down with Bioxyne’s (ASX:BXN) founder and CEO Sam Watson to get the short end of the long story on the company’s latest news. Bioxyne, the parent company of Breath Life Sciences, has manufactured and deliver...

ASX ended 10-day winning streak ANZ, Tabcorp dropped after facing regulators Despite a crude price rebound, energy stocks fell   The ASX 200 ended its 10-day winning streak, dipping by 0.04% after a weak session on Wall Street overnight....

Good morning, and welcome to Stockhead’s Top 10 at somewher enear 11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

ASX 200 banked its 10th straight win, climbing 0.21pc to 8,027.00 points InfoTech and Resources were the stand-out sectors today Who won among the small caps? You’ll need to read on to find out   The ASX has hit 10 winners in a row, which...

THC gummies are becoming popular for their convenience and effects Bioxyne has produced Australia’s first GMP-certified cannabis gummies Bioxyne is expanding production to meet rising demand   Functional foods are growing in popularity as...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

ASX rises circa 0.5pc Consumer stocks in focus this week SGQ and PHX lead small caps   Aussie stocks have closed higher on Monday as IT and retail stocks added strength to sentiment. The S&P/ASX200 closed higher, gaining 36.00 points...

Good morning, and welcome to Stockhead’s Top 10 at around 11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading...

The ASX dropped, dragged down by Real Estate and Mining stocks Qantas cuts former CEO’s compensation by $9.3m Fears of a US recession are growing, with the Sahm Rule signalling potential trouble   A selloff in Real Estate and Mining stock...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish – with the best (and sometimes worst) performing ASX stocks in morning trade. We use live data to help frame the ASX trading day through the biggest movers in percenta...

Good morning, and welcome to Stockhead’s Top 10 at shortly-after-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the t...

  ASX 200 hit by afternoon profit taking, closing at +0.1pc for the day. 9 of 11 ASX sectors were higher, so… two of them weren’t. Small cap gains led by East33, and the world is their oyster.   Local markets trimmed most of the early mor...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX200 dropped on Friday, extending its weekly loss despite Wall Street’s highs Telix Pharma halted US IPO; Tabcorp jumps 10pc on NSW tax reform Germany works to soften EU tariffs on Chinese electric cars   The ASX200 dropped by -0.3% on...

Aussie dairy industry finds itself in a ‘perfect storm’ Dairy processors such as Beston are proactively embracing innovations to survive Despite the hurdles, investors with patience might find promising prospects ahead   The current crisi...

Aussie stocks fell 1pc on rising inflation ASX sectors mostly down; IAG hit by class action lawsuit Asian markets dropped; IMF ups China’s growth forecast to 5pc   Aussie stocks fell by 1% on Wednesday, hitting their lowest point in three...

Bioxyne emphasises importance of stringent regulatory frameworks for safe use of psychedelics and cannabis Company highlights risks of incorrect dosages, impure substances, and lack of medical supervision Bioxyne subsidiary awarded Austral...

  Subsidiary of Bioxyne enters deal with Cy Biopharma AG of Switzerland Companies will develop psilocybin products to treat depression and pain in Australia and New Zealand markets Deal enables manufacture and supply of Australian, New Zea...

ASX flat on Monday,  ahead of Federal Budget Tuesday night Oil weakness drags Energy sector lower Chinese shares slump on new US tariffs   After advancing 1.5% last week, the ASX200 fell flat on Monday – greenish by 0.01% – dragged down m...